Additionally, molecular docking predicted that existing compounds, such as captopril and menadione, could effectively bind to the EP300 protein.<h4>Conclusion</h4>Our study provides genetic evidence establishing EP300 and P2RY14 as promising drug targets for the treatment of IBS, laying a foundation for future drug development and repurposing efforts. This evidence concerns the gene EP300 and irritable bowel syndrome.